RxDoctor Payments Data

Anatole Trakhtenbroit, MD

Cardiovascular Disease · San Antonio, TXNPI 1972580967

Payments from drug & device makers

$3,419in general payments, 2019–2025

Across 21 payments — averaging $162.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GE HealthCare$3K
  • E.r. Squibb & Sons, L.L.C.$114
  • Lantheus Medical Imaging, Inc.$103
  • Amgen$79
  • Pfizer$78
  • Alnylam Pharmaceuticals Inc.$73
  • plus $112 from 4 others

What the payments were for

  • Consulting fees$2,28867%
  • Speaking & faculty fees$57217%
  • Food & beverage$54716%
  • Education$120%

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,419 in reported general payments places this provider in the 45th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$116,410
Medicare patients
776
Services billed
1,979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndaqelTafamidis Meglumine11$223,692
EliquisApixaban103$120,853
FarxigaDapagliflozin Propanediol26$29,469
XareltoRivaroxaban18$21,882
BrilintaTicagrelor11$11,537
Repatha SureclickEvolocumab17$9,739
Amiodarone Hcl26$1,805
Losartan Potassium157$1,378
Metoprolol Succinate95$1,334
Atorvastatin Calcium145$1,264
Carvedilol149$1,050
ClopidogrelClopidogrel Bisulfate69$919
Potassium Chloride65$783
Ezetimibe27$779
Rosuvastatin Calcium69$721

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndaqel, Eliquis$78$344,544114 claims
Johnson & JohnsonXarelto$21$21,88218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →